484. Clinical Description of SARS-CoV-2 Infection in Patients with Primary Antibody Deficiency Who Received Tixagevimab/Cilgavimab Prophylaxis

BACKGROUND: Patients with primary antibody deficiency are known to be associated with a higher risk of SARS-CoV-2 infection, complications, and mortality. Tixagevimab/Cilgavimab prophylaxis has shown efficacy in reducing hospitalization and mortality. We aim to describe the clinical characteristics...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Sung Min, Shin, Je Hee, Baek, Jee Yeon, Lee, Ji Young, Kang, Ji-Man, Ahn, Jong Gyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677890/
http://dx.doi.org/10.1093/ofid/ofad500.554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677890/
http://dx.doi.org/10.1093/ofid/ofad500.554

Ejemplares similares